Differences in Prostate Cancer between Korean Patients, the European Randomized Study of Screening for Prostate Cancer/Rotterdam Group, and a Dutch Clinical Cohort

다국어 초록 (Multilingual Abstract)

Purpose: We evaluated differences in biopsy-detected prostate cancer (PC) between a newly defined Korean clinical cohort (KCC) and two Western populations.
Materials and Methods: The records of 723 Korean men aged 55 to 75 years who underwent an initial transrectal ultrasound-guided biopsy from 2004 to 2010 were retrospectively reviewed. Prostate biopsies were performed due to prostate-specific antigen (PSA) levels greater than 4.0ng/ml, or suspicious findings on rectal examination or transrectal ultrasonography. Characteristics of PC were compared between the KCC and Western groups (the Rotterdam group of the European Randomized Study of Screening for Prostate Cancer: ERSPC and Dutch Clinical Cohort: DCC).
Results: The cancer detection rate was 26.4% (191/723) in the KCC, 20.9% (473/2268) in the ERSPC/Rotterdam group and 43.1% (138/320) in the DCC. The median PSA in patients with PC was 11.8ng/ml, 5.7ng/ml and 7.5ng/ml in the KCC, ERSPC/Rotterdam group, and DCC, respectively. The proportion of patients with a Gleason score of 7 or more was 57.1% (109/191) in the KCC, 37.5% (174/464) in the ERSPC/Rotterdam group and 37.0% (51/138) in the DCC.
Conclusions: We found large differences in cancer detection rate, PSA, and Gleason score distribution between the KCC and Western cohorts. PC detected in Korean patients had more advanced clinical factors than in Western populations due to low availability of PSA screening programs.

참고문헌 (Reference)

1 Oakley-Girvan I, "Stage at diagnosis and survival in a multiethnic cohort of prostate cancer patients" 93 : 1753-1759, 2003

2 Jeong CW, "Seoul National University Prostate Cancer Stage Calculator: Generalization and Head-to-Head Comparison with 2013 Partin Table by Multicenter Cohort" 11 : 133-140, 2013

3 Moyer VA, "Screening for prostate cancer: US Preventive Services Task Force recommendation statement" 157 : 120-134, 2012

4 Park SK, "Rising prostate cancer rates in South Korea" 66 : 1285-1291, 2006

5 변석수, "Recent Changes in the Clinicopathologic Features of Korean Men with Prostate Cancer: A Comparison with Western Populations" 연세대학교의과대학 53 (53): 543-549, 2012

6 Oberaigner W, "Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008" 57 : 57-62, 2012

7 Schröder FH, "Prostate-cancer mortality at 11 years of follow-up" 366 : 981-990, 2012

8 Andriole GL, "Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up" 104 : 125-132, 2012

9 Song C, "Prostate cancer in Korean men exhibits poor differentiation and is adversely related to prognosis after radical prostatectomy" 68 : 820-824, 2006

10 Raymundo EM, "Prostate cancer in Asian Americans: incidence, management and outcomes in an equal access healthcare system" 107 : 1216-1222, 2011

11 van Vugt HA, "Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort" 48 : 1809-1815, 2012

12 van Vugt HA, "Prediction of prostate cancer in unscreened men: external validation of a risk calculator" 47 : 903-909, 2011

13 Jeong CW, "Mobile application-based Seoul National University Prostate Cancer Risk Calculator: development, validation, and comparative analysis with two Western risk calculators in Korean men" 9 : e94441-, 2014

14 Finne P, "Lead-time in the European randomised study of screening for prostate cancer" 46 : 3102-3108, 2010

15 Kang DI, "Korean Prostate Cancer Patients Have Worse Disease Characteristics than their American Counterparts" 14 : 6913-, 2013

16 "Korea National Cancer Center National cancer registration and statistics 2008"

17 박재영, "Initial Biopsy Outcome Prediction in Korean Patients- Comparison of a Novel Web-based Korean Prostate Cancer Risk Calculator versus Prostate-specific Antigen Testing" 대한의학회 26 (26): 85-91, 2011

18 Holmes Jr L, "Impact of androgen deprivation therapy on racial/ethnic disparities in survival of older men treated for locoregional prostate cancer" 16 : 176-, 2009

19 Roobol M, "Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands)" 92 : 48-54, 2003

20 Zhu Y, "External validation of the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer risk calculators in a Chinese cohort" 14 : 738-744, 2012

21 Kimura T, "East meets West: ethnic differences in prostate cancer epidemiology between East Asians and Caucasians" 31 : 421-429, 2012

22 Takahashi H, "Differences in prostate cancer grade, stage, and location in radical prostatectomy specimens from United States and Japan" 74 : 321-325, 2014

23 Fukagai T, "Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men" 97 : 1190-1193, 2006

24 Siegel R, "Cancer statistics, 2012" 62 : 10-29, 2012

25 Arnold M, "Cancer risk diversity in non-western migrants to Europe: An overview of the literature" 46 : 2647-2659, 2010

26 McCracken M, "Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities" 57 : 190-205, 2007

27 Miller BA, "Cancer incidence and mortality patterns among specific Asian and Pacific Islander populations in the US" 19 : 227-256, 2008

28 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2011" 대한암학회 46 (46): 109-123, 2014

29 Yoon DK, "Can the prostate risk calculator based on western population be applied to asian population?" 72 : 721-729, 2012

30 Man A, "Asian race and impact on outcomes after radical radiotherapy for localized prostate cancer" 170 : 901-904, 2003

31 Xia SJ, "An overview of prostate diseases and their characteristics specific to Asian men" 14 : 458-464, 2012